Anixa Biosciences, Inc. ANIX 深 滬
等待開盤 08-13 09:30:00 美东时间
3.04
+0.100
+3.40%
華盛通- 最 高3.0997
- 今 開2.97
- 成交量 9.68万股
- 最 低 2.9507
- 昨 收 2.94
- 總市值 9792.17万
- 52周最高 4.20
- 市盈率 靜 --
- 換手率 0.30%
- 52周最低 2.07
- 委 比 -88.07%
- 總股本 3221.11万
- 歷史最高 8.09
- 量 比 1.21
- 振 幅 5.07%
- 歷史最低 1.33
- 每 手 1
- 風險率 0.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology
Newly issued patent extends protection of proprietary solid tumor CAR-T platform to 2045 SAN JOSE, Calif., Aug. 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (N...
08-12 20:05
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy
Annexon, Inc. announced that its vonaprument (formerly ANX007) has been selected by the European Medicines Agency (EMA) to participate in the Product Development Coordinator (PDC) pilot, aimed at streamlining regulatory interactions and evidence planning. Vonaprument, a first-in-kind antibody fragment targeting C1q in the eye, has the potential to become the first approved treatment for dry age-related macular degeneration (AMD) with geographic a...
08-07 20:30
Anixa Biosciences Advances Breast Cancer Vaccine To Phase 2, Initiates IND Transfer From Cleveland Clinic Following Phase 1 Results
Progress Follows Positive Immune Response Observed in Phase 1 StudySAN JOSE, Calif., Aug. 4, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on
08-04 20:45
Anixa Biosciences Announces It Has Been Awarded A New U.S. Patent Extending Its Breast Cancer Vaccine IP Protection Into The 2040's
Patent Expands Immunogenic Coverage of α-Lactalbumin-Based Vaccine PlatformTechnology Addresses Substantial Unmet Need in Preventive Oncology with Multi-Billion Dollar Market Potential Anixa Biosciences,
07-24 20:03
Anixa Biosciences to Host an Investor Webcast on June 26, 2025
SAN JOSE, Calif., June 20, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, ...
06-20 19:30
Anixa Biosciences To Present e-Poster On Ovarian Cancer CAR-T Clinical Trial At ESMO Gynaecological Cancers Congress 2025
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology
06-09 20:06
Anixa Biosciences Completes Enrollment In Phase 1 Clinical Trial Of Breast Cancer Vaccine
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the completion of enrollment in the Phase 1 clinical trial of
06-02 19:04
美股大行评级 | 英伟达、赛富时、C3.ai、Veeva Systems等获多家机构上调目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1135136987677396993.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Cogent Biosciences(COGT)"超配"评级，目标价从21美元升至25美元</p> <p>• Chardan Capital：维持Taysha Gene Therapies(TSHA)"买入"
05-30 09:09
D. Boral Capital Maintains Buy on Anixa Biosciences, Maintains $10 Price Target
D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $10 price target.
05-29 19:23
Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report
CytomX reported early Phase 1 data for CX-2051 in advanced colorectal cancer, with a 94% disease control rate.
05-12 23:11
